BRNS

Barinthus Biotherapeutics Plc. - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Barinthus Biotherapeutics Plc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for autoimmune and inflammatory diseases (I&I). The company recently announced a strategic pivot to prioritize its I&I pipeline, specifically the lead candidate VTP-1000 for celiac disease, while deprioritizing its infectious disease and oncology programs. As of June 30, 2025, the company had 40,348,665 ordinary shares outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• General and Administrative (G&A) Expenses: Increased significantly to $15.4M in Q2 2025 from $7.2M in Q2 2024. This $8.2M increase was primarily driven by an $8.0M unrealized foreign exchange loss due to the translation of USD balances in GBP-denominated entities, alongside a $2.0M increase in professional fees related to strategic activities.
• Research and Development (R&D) Expenses: Decreased to $8.0M in Q2 2025 from $11.7M in Q2 2024. The $3.7M reduction reflects the strategic decision to deprioritize infectious disease and oncology programs, offset slightly by increased spend on the VTP-1000 celiac program.
• Other Income: Increased to $0.3M in Q2 2025 from $0.02M in Q2 2024, primarily due to a $0.3M gain on the disposal of U.K. laboratory equipment.
• Foreign Exchange Impact: The company recognized a net foreign exchange loss of $12.4M in G&A expenses for the six months ended June 30, 2025, compared to a $1.1M gain in the prior year period.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, and restricted cash ($87.8M) to fund operations into the start of 2027. The company anticipates incurring net losses for the foreseeable future and may require additional financing through equity, debt, or collaborations.
• Strategic Pivot: The company is exiting the CEPI Funding Agreement for VTP-500 (MERS) to align resources with the I&I strategy. In August 2025, the company ceased R&D activities in its Harwell, U.K. laboratory and is transitioning the workforce to remote roles while marketing the facility for sublease.
• Clinical Progress: The Phase 1 AVALON trial for VTP-1000 (celiac disease) has dosed the first two cohorts with no serious adverse events. The multiple ascending dose cohort opened in July 2025.
• Risks:
  • Regulatory Environment: Potential disruptions at the FDA and SEC due to government funding issues, staffing reductions, or policy changes under the new U.S. administration could delay reviews and approvals.
  • Foreign Exchange: Significant exposure to fluctuations between the U.S. Dollar and Pound Sterling, which materially impacted G&A expenses in the current period.
  • Capital Needs: Failure to secure additional funding could force the company to delay or terminate development programs.

Key Facts for Investor Verification

• Verify the sustainability of the $8.0M foreign exchange loss included in G&A expenses and its impact on future earnings volatility.
• Confirm the timeline and cost implications of the U.K. laboratory exit and the transition to remote operations.
• Monitor the progress of the VTP-1000 Phase 1 trial and the company's ability to secure partners for the VTP-300 (Hepatitis B) program.
• Assess the impact of the CEPI Funding Agreement exit on future grant income and the utilization of the remaining $1.5M in restricted cash.
• Review the contingent consideration liability of $2.5M related to the Avidea Technologies acquisition and the probability of achieving the associated milestones.